- Home
- VCV vs URGN Comparison
VCV vs URGN Comparison
Compare VCV & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCV
- URGN
- Stock Information
- Founded
- VCV 1993
- URGN 2004
- Country
- VCV United States
- URGN United States
- Employees
- VCV N/A
- URGN N/A
- Industry
- VCV Trusts Except Educational Religious and Charitable
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- VCV Finance
- URGN Health Care
- Exchange
- VCV Nasdaq
- URGN Nasdaq
- Market Cap
- VCV 518.7M
- URGN 463.2M
- IPO Year
- VCV N/A
- URGN 2017
- Fundamental
- Price
- VCV $10.59
- URGN $10.38
- Analyst Decision
- VCV
- URGN Strong Buy
- Analyst Count
- VCV 0
- URGN 7
- Target Price
- VCV N/A
- URGN $36.75
- AVG Volume (30 Days)
- VCV 107.9K
- URGN 651.7K
- Earning Date
- VCV 01-01-0001
- URGN 05-12-2025
- Dividend Yield
- VCV 4.09%
- URGN N/A
- EPS Growth
- VCV N/A
- URGN N/A
- EPS
- VCV 0.13
- URGN N/A
- Revenue
- VCV N/A
- URGN $90,398,000.00
- Revenue This Year
- VCV N/A
- URGN $36.82
- Revenue Next Year
- VCV N/A
- URGN $119.10
- P/E Ratio
- VCV $75.82
- URGN N/A
- Revenue Growth
- VCV N/A
- URGN 9.29
- 52 Week Low
- VCV $8.05
- URGN $8.94
- 52 Week High
- VCV $10.40
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- VCV 61.50
- URGN 48.46
- Support Level
- VCV $9.90
- URGN $9.63
- Resistance Level
- VCV $10.64
- URGN $11.75
- Average True Range (ATR)
- VCV 0.16
- URGN 0.82
- MACD
- VCV 0.09
- URGN -0.02
- Stochastic Oscillator
- VCV 94.79
- URGN 32.90
About VCV Invesco California Value Municipal Income Trust
Invesco California Value Municipal Income Trust is engaged in the field of financial services. Its objective is to seek to provide common shareholders with a high level of current income exempt from federal and California income taxes, consistent with preservation of capital.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.